Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
← catalyst calendarNCT07516093 · readout ≤ 1,169 d
Sponsored by Nurix Therapeutics, Inc. (industry) · NRIX — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
620estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2026 | estimated | When the study began enrolling |
| Primary completion | Oct 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- B-cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- Drug: NX-5948 — also filed as Bexobrutideg
- Drug: Pirtobrutinib — also filed as JAYPIRCA
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS) as assessed by Independent Review Committee (IRC)
measured Up to approximately 3.5 years
Permalink · NRIX's whole pipeline · Catalyst calendar · Every registered study · What changed